Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Will the first two biotech IPOs of the year — both upsized — pave the way for a rosy public market? How about the outlook for buyouts? Don’t miss our analysis on these topics, and stay tuned as we find out Big Pharma’s view at earnings next week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.